Findings show that the MRMC framework was feasible in a practice-proximate setting and the trends merit further evaluation in larger cohorts and earlier diagnostic settings.
Abstract
We assessed the feasibility of a multi-reader, multi-case (MRMC) observer-performance design to evaluate the simulated decision impact of a radiomics-based computer-assisted diagnostic tool (CADx) and a methylated circulating tumour DNA (ctDNA) assay in lung cancer work-up. Patients referred to a Danish fast-track lung cancer clinic were enrolled. Baseline chest CT scans were analysed with the CADx RevealAI-Lung and plasma with a five-target methylated ctDNA assay. Virtual cases were presented in four information sets: standard of care (SoC), SoC plus ctDNA, SoC plus CADx, and SoC plus both tests. Four pulmonologists independently triaged each case. Diagnostic performance was evaluated using ROC analyses, and triage patterns were compared across information sets. The cohort comprised 239 participants, including 104 lung cancer cases and 135 cancer-free subjects, resulting in 956 unique cases. Both the CADx result and ctDNA positivity were associated with lung cancer. Discrimination was high and similar across information sets (AUC 0.84 to 0.86), with no significant differences. Additional information produced modest, non-significant shifts, mainly among cancer-free subjects, with the combined set tending towards fewer nodule follow-up allocations and more discharges. These findings show that the MRMC framework was feasible in a practice-proximate setting and the trends merit further evaluation in larger cohorts and earlier diagnostic settings.
Lung cancer remains the leading cause of cancer-related death worldwide, largely due to late-stage diagnosis. Although low-dose computed tomography (LDCT) screening can reduce mortality, it is limited by high false-positive rates, radiation exposure, and low adherence. Thus, there is an urgent need for precise, accessi...
Peter Hjorth-Hansen, C. Jacobsen, L. Nederby et al.· Journal of Molecular Diagnos...· 0 citations
Introduction: Multiparametric MRI (mpMRI) interpreted using Prostate Imaging Reporting and Data System (PI-RADS) v2.1 is central to prostate cancer (PCa) assessment, but inter-reader variability remains a concern. This study evaluated inter-reader agreement, diagnostic performance, the utility of prostate-specific anti...
M. Abufaraj, Sarah B. Al-Qalalweh, Ahmad S. Kreishan et al.· Diagnostics· 0 citations
BACKGROUND
Multi-biomarker blood tests have the potential to detect a broad range of cancer types and stages. Herein, we assessed the performance of a methylation and protein (MP) classifier using samples from a large, multi-center, prospectively collected case-control study. As part of the assay development process, w...
Vladimir G. Gainullin, Mael Manesse, Fang-Lei Zhuang et al.· Cancer Epidemiology, Biomark...· 0 citations
The NHS-Galleri trial was a randomized controlled trial evaluating a multi-cancer early detection (MCED) test added to usual care. We reported elsewhere that the primary endpoint of a reduction in the incidence of stage III/IV cancer diagnoses in the intervention arm versus control arm was not met. Here we report presp...
Richard D. Neal, S. Dolly, Peter Johnson et al.· Nature Medicine· 4 citations
ChatGPT achieved the highest overall concordance, although all models generated clinically acceptable recommendations in most cases, and all LLMs demonstrated high concordance with consultant-led thyroid cancer MDT decisions.
A. White, Kerry A. Leyton, N. Patel et al.· Updates in Surgery· 0 citations
Early cancer detection improves survival; however, most cancer types do not have guideline-recommended screening. We previously reported the first PATHFINDER study that established feasibility of cancer screening with a blood-based multi-cancer early detection (MCED) test that predicts cancer signal origin (CSO) to gui...
N. Nabavizadeh, C. McDonnell, D. Kurbegov et al.· Nature Medicine· 3 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.